Furthermore, a retrospective review of 73 patients with confirmed dMMR/MSI-H colorectal cancer who received any type of programmed cell death-1 (PD-1) inhibitor prior to surgery showed that 84.9% of patients achieved an objective response, with 23.3% showing a complete response, and 61.6% a partial response. Here, PDCD1 is linked to colorectal cancer.